# Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

> **NCT03283202** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 35 (actual)

## Conditions studied

- Diffuse B-Cell Lymphoma

## Interventions

- **DRUG:** Avadomide (CC-122)
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide 750mg/m2 by IV infusion
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03283202
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-04
- **Primary completion:** 2019-07-30
- **Final completion:** 2020-12-16
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283202, "Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03283202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*